433.07
-20.67 (-4.56%)
| 前收盘价格 | 453.74 |
| 收盘价格 | 450.95 |
| 成交量 | 1,915,411 |
| 平均成交量 (3个月) | 1,440,454 |
| 市值 | 110,014,586,880 |
| 市盈率 (P/E TTM) | 28.25 |
| 预期市盈率 (P/E Forward) | 23.81 |
| 价格/销量 (P/S) | 9.76 |
| 股市价格/股市净资产 (P/B) | 6.18 |
| 52周波幅 | |
| 利润日期 | 4 May 2026 |
| 营业毛利率 | -8.91% |
| 营业利益率 (TTM) | 37.22% |
| 稀释每股收益 (EPS TTM) | -3.80 |
| 季度收入增长率 (YOY) | 3.00% |
| 季度盈利增长率 (YOY) | -41.20% |
| 总债务/股东权益 (D/E MRQ) | 10.00% |
| 流动比率 (MRQ) | 2.65 |
| 营业现金流 (OCF TTM) | -980.30 M |
| 杠杆自由现金流 (LFCF TTM) | 2.63 B |
| 资产报酬率 (ROA TTM) | 11.77% |
| 股东权益报酬率 (ROE TTM) | -5.64% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Vertex Pharmaceuticals Incorpor | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Value |
| 内部持股比例 | 0.15% |
| 机构持股比例 | 97.64% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 641.00 (HC Wainwright & Co., 48.01%) | 购买 |
| 中 | 558.00 (28.85%) | |
| 低 | 441.00 (Canaccord Genuity, 1.83%) | 保留 |
| 平均值 | 557.40 (28.71%) | |
| 总计 | 12 购买, 3 保留 | |
| 平均价格@调整类型 | 488.67 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 11 Mar 2026 | 525.00 (21.23%) | 购买 | 492.38 |
| B of A Securities | 10 Mar 2026 | 598.00 (38.08%) | 购买 | 499.17 |
| Citigroup | 10 Mar 2026 | 585.00 (35.08%) | 购买 | 499.17 |
| HC Wainwright & Co. | 10 Mar 2026 | 641.00 (48.01%) | 购买 | 499.17 |
| 17 Feb 2026 | 591.00 (36.47%) | 购买 | 477.32 | |
| Jefferies | 10 Mar 2026 | 580.00 (33.93%) | 购买 | 499.17 |
| Morgan Stanley | 10 Mar 2026 | 596.00 (37.62%) | 购买 | 499.17 |
| Oppenheimer | 10 Mar 2026 | 600.00 (38.55%) | 购买 | 499.17 |
| 13 Feb 2026 | 540.00 (24.69%) | 购买 | 491.47 | |
| Barclays | 17 Feb 2026 | 607.00 (40.16%) | 购买 | 477.32 |
| 28 Jan 2026 | 606.00 (39.93%) | 购买 | 477.91 | |
| Canaccord Genuity | 17 Feb 2026 | 441.00 (1.83%) | 保留 | 477.32 |
| RBC Capital | 13 Feb 2026 | 541.00 (24.92%) | 购买 | 491.47 |
| 22 Jan 2026 | 546.00 (26.08%) | 购买 | 467.35 | |
| Scotiabank | 13 Feb 2026 | 558.00 (28.85%) | 保留 | 491.47 |
| Stifel | 13 Feb 2026 | 466.00 (7.60%) | 保留 | 491.47 |
| UBS | 26 Jan 2026 | 545.00 (25.85%) | 购买 | 476.84 |
| 07 Jan 2026 | 535.00 (23.54%) | 购买 | 484.15 | |
| Evercore ISI Group | 23 Jan 2026 | 530.00 (22.38%) | 购买 | 468.41 |
| Wolfe Research | 06 Jan 2026 | 548.00 (26.54%) | 购买 | 468.38 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合